Lazard Asset Management’s BeOne Medicines ONC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$43.1M Buy
117,700
+27,352
+30% +$9.35M 0.06% 238
2026
Q2
$25.7M Buy
90,348
+27,431
+44% +$8.08M 0.04% 304
2026
Q1
$18.7M Buy
62,917
+14,696
+30% +$4.76M 0.03% 332
2025
Q4
$14.7M Buy
48,221
+6,841
+17% +$2.24M 0.02% 366
2025
Q3
$14.1M Buy
41,380
+17,688
+75% +$5.37M 0.02% 365
2025
Q2
$5.74M Buy
23,692
+11,197
+90% +$2.75M 0.01% 693
2025
Q1
$3.4M Buy
+12,495
New +$2.92M 0.01% 806
2021
Q3
– Sell
-3,055
Closed -$1.05M – 2318
2021
Q2
$1.05M Buy
+3,055
New +$1.01M ﹤0.01% 943
2021
Q1
– Sell
-689
Closed -$178K – 2058
2020
Q4
$178K Hold
689
– – ﹤0.01% 1113
2020
Q3
$197K Buy
+689
New +$162K ﹤0.01% 967
2018
Q1
– Sell
-1,580
Closed -$154K – 1134
2017
Q4
$154K Buy
+1,580
New +$145K ﹤0.01% 894

Other funds holding ONC

Lazard Asset Management's ONC Position: Q3 2026 in Review

Lazard Asset Management increased its BeOne Medicines (ONC) stake by 30% in Q3 2026, buying an estimated $9.35M and bringing the position to 117,700 shares worth $43.1M. The position accounts for 0.06% of the portfolio, ranked #238.

Lazard Asset Management first reported a position in ONC in Q4 2017 and has held it in 11 quarters since. 325 funds tracked by Wall St. Rank hold ONC as of Q3 2026.

  • Lazard Asset Management held 117,700 shares of BeOne Medicines worth $43.1M as of Q3 2026.
  • Lazard Asset Management bought 27,352 BeOne Medicines shares in Q3 2026, an estimated $9.35M.
  • BeOne Medicines made up 0.06% of Lazard Asset Management's portfolio in Q3 2026, its #238 holding.
  • Lazard Asset Management first reported a position in BeOne Medicines in Q4 2017 and has held it in 11 quarters since.
  • 325 funds tracked by Wall St. Rank held BeOne Medicines as of Q3 2026.

Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.